#CD47

Looking into the literature, it seems like specifically targeting CD47 with an active IgG might maximize the ADCC of the IgG relative to other targets. There are 2 reasons for
Read more
Interesting Merck valued VelosBio's ROR1-based antibody technology at 2.75 billion with only preclinical data available. VelosBio's VLS-101 is an antibody carrying a spindle poison payload, which is toxic to all
Read more
Has $TRIL ever suggested a reason for WHY its drugs don't bind to human red blood cells?2017 paper in deck suggests: "association of #CD47 w erythrocyte spectrin cytoskeleton, which results
Read more
$TRIL $ALXO -- A Fair Comparison $TRIL & $ALXO have chosen 2 very different paths to CD47 inhibition & how we evaluate:- TTI-622/ (621, to come)- ALX148 Early progress ought
Read more
$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread $TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread Trillium, in
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.